Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract

Summary

Spleen cells of BALB/c mice that had been inoculated with syngeneic plasmacytoma MOPC 104E were cultured for 11 days in T-cell growth factor (TCGF) and ultrasonicated tumor extract (USE). Cultured lymphocytes (MOPC-CL) possessed three-fold more lytic units than normal spleen cells cultured in TCGF without USE (N-CL). Moreover, the in vivo neutralization assay suggested that MOPC-CL were composed of at least two populations, one possessing tumor-specific and the other nonspecific antitumor activity. When 2×107 of MOPC-CL were administered IP to mice that had been inoculated IP with 105 MOPC 104E cells 5 days previously marginal prolongation of survival was observed. This effect was not augmented by the single injection of a larger number (5×107) of CL, but was augmented by the repeated daily administration for 4 days (from day 5 to day 8 after the inoculation) of the same total number (5×107) of CL. In addition, IP injection of the streptococcal preparation OK432 before the transfer of CL significantly enhanced the therapeutic efficacy, and resulted in a cure rate of 20%. The mechanism of this combined effect appears to involve the effect of OK432 on interleukin 2 (IL-2) regulation systems in vivo. Our culture system with TCGF and USE and our therapy system with OK432 and CL allow the clinical application of adoptive immunotherapy for the many types of solid cancers.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Burton R, Thompson J, Warner NL (1975) In vitro induction of tumor-specific immunity. I. Development of optimal conditions for induction and assay of cytotoxic lymphocytes. J Immunol Methods 8:133

  2. 2.

    Cheever MA, Greenberg PD, Fefer A (1981) Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin 2. J Immunol 126:1318

  3. 3.

    Cheever MA, Greenberg PD, Fefer A, Gillis S (1982) Augmentation of the anti-tumor therapeutic efficacy of long-term cultred T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 155:968

  4. 4.

    Donohue JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203

  5. 5.

    Eberlein TJ, Rosenstein M, Spiess P, Wesley R, Rosenberg SA (1982a) Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor. Cancer Immunol Immunother 13:5

  6. 6.

    Eberlein TJ, Rosenstein M, Rosenberg SA (1982b) Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med 156:385

  7. 7.

    Ebina T, Sakai A, Saito M, Yamaguchi T et al. (1981) Interferon induction and augmentation of natural killer cell activity by immunopotentiators. Igaku No Ayumi 117:230

  8. 8.

    Engers HD, Thomas K, Cerottini JC, Brunner KT (1975) Generation of cytotoxic T lymphocytes in vitro. V. Response of normal and immune spleen cells to subcellular alloantigens. J Immunol 115:356

  9. 9.

    Farrar WL, Johnson HM, Farrar JJ (1981) Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol 126:1120

  10. 10.

    Fernandez-Cruz E, Gilman SC, Feldman JD (1982) Immunotherapy of a chemically-induced sarcoma in rats: Characterization of the effector T cell subsets and nature of suppression. J Immunol 128:1112

  11. 11.

    Gillis S, Smith KA (1977) Long-term culture of tumor-specific cytotoxic T cells. Nature 268:154

  12. 12.

    Gillis S, Ferm MM, Ou W, Smith KA (1978) T cell growth factor: Parameters of production and a quantitative microassay for activity. J Immunol 120:2027

  13. 13.

    Hori T, Kan N, Yamasaki N, Nakayama N, Nio Y, Ohgaki K, Inamoto T (1984) Specific cytotoxic activity of tumor infiltrating lymphocytes (TIL) in murine mammary carcinoma. J. Jpn Surg Soc (in press)

  14. 14.

    Inamoto T, Kan N, Ohgaki K, Hikasa Y (1983) Different immunosuppression on specific anti-tumor and non-specific cellular immunity of tumor-bearing mice following tumor growth. Arch Jpn Chir 52:196

  15. 15.

    Kan N, Ohgaki K, Inamoto T, Yamasaki N, Nio Y, Hikasa Y (1983a) Specific adoptive immunotherapy by local transfer of cultured syngeneic spleen cells for mammary carcinoma in mice. Arch Jpn Chir 52:185

  16. 16.

    Kan N, Ohgaki K, Yamasaki N, Hori T, Nakayama N, Nio Y, Inamoto T, Hikasa Y (1983b) Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: A clinical trial. Arch Jpn Chir 52:841

  17. 17.

    Kedar E, Unger E, Schwärzbach M (1976) In vitro induction of cell-mediated immunity to murine leukemia cells. I. Optimization of tissue culture conditions for the generation of cytotoxic lymphocytes. J Immunol Methods 13:1

  18. 18.

    Kedar E, Raanan Z, Schwärzbach M (1978) In vitro induction of cell-mediated immunity to murine leukemia cells. VI. Adoptive immunotherapy in combination with chemotherapy of leukemia in mice, using lymphocytes sensitized in vitro to leukemia cells. Cancer Immunol Immunother 4:161

  19. 19.

    Kedar E, Ikejiri BL, Gorelik E, Herberman RB (1982) Natural cell mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF). Cancer Immunol Immunother 13:14

  20. 20.

    Klein E, Vánky F (1981) Natural and activated cytotoxic lymphocytes which act on autologous and allogeneic tumor cells. Cancer Immunol Immunother 11:183

  21. 21.

    Lotze MT, Line BR, Mathisen DJ, Rosenberg SA (1980) The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J Immunol 125:1487

  22. 22.

    Macdonald HR, Engers HD, Cerottini JC, Brunner KT (1974) Generation of cytotoxic T lymphocytes in vitro. II. Effect of repeated exposure to alloantigens on the cytotoxic activity of long-term mixed leukocyte culture. J Exp Med 140:718

  23. 23.

    Mills GD, Carlson G, Paetkau V (1980) Generation of cytotoxic lymphocytes to syngeneic tumors by using costimulator (interleukin 2): in vivo activity. J Immunol 125:1904

  24. 24.

    Mokyr MB, Braun DP, Usher D, Reiter H, Dray S (1978) The development of in vitro and in vivo antitumor cytotoxicity in noncytotoxic, MOPC315-tumor-bearer, spleen cells “educated” in vitro with MOPC315 tumor cells. Cancer Immunol Immunother 4:143

  25. 25.

    Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007

  26. 26.

    Okamoto H, Shoin S, Koshimura S, Shimizu R (1973) Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 11:323

  27. 27.

    Röllinghoff M, Wagner H (1973) In vivo protection against murine plasma cell tumor growth by in vitro activated syngeneic lymphocytes. J Natl Cancer Inst 51:1317

  28. 28.

    Simon PL, Farrar JJ, Kind PH (1979) Biochemical relationship between murine immune interferon and a killer cell helper factor. J Immunol 122:127

  29. 29.

    Spiess PJ, Rosenberg SA (1981) A simplified method for the production of murine T-cell growth factor free of lectin. J Immunol Methods 42:213

  30. 30.

    Treves AJ, Cohen IR, Feldman M (1975) Immunotherapy of lethal metastasis by lymphocytes sensitized against tumor cells in vitro. J Natl Cancer Inst 54:777

  31. 31.

    Torisu M, Katano M, Kimura Y, Itoh H, Takesue M (1983) New approach to management of malignant ascites with a streptococcal preparation, OK432. I. Improvement of host immunity and prolongation of survival. Surgery 93:357

  32. 32.

    Uchida A, Hoshino T (1980) Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 45:476

  33. 33.

    Uchida A, Micksche M (1983) Intrapleural administration of OK432 in cancer patients: Activation of NK cells and reduction of suppressor cells. Int J Cancer 31:1

  34. 34.

    Vose BM, Vánky F, Fopp M, Klein E (1978) In vitro generation of cytotoxicity against autologous human tumor biopsy cells. Int J Cancer 21:588

  35. 35.

    Vose BM, Bonnard GD (1983) Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells. J Immunol 130:687

  36. 36.

    Wagner H, Röllinghoff M (1973) In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors. J Exp Med 138:1

  37. 37.

    Wakasugi H (1982) In vitro potentiation of human natural killer (NK) cell activity by a streptococcal preparation, OK432. J Jpn Surg Soc 83:38

  38. 38.

    Winn HJ (1961) Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homograft. J Immunol 86:228

  39. 39.

    Yamasaki N, Kan N, Inamoto T, Nakayama N, Nio Y, Hori T, Hikasa Y (1984) In vivo kinetics of murine lymphoid cells in relation to local adoptive immunotherapy. Arch Jpn Chir (in press)

  40. 40.

    Yamauchi K, Fujimoto S, Tada T (1979) Differential activation of cytotoxic and suppressor T cells against syngeneic tumors in the mice. J Immunol 123:1653

Download references

Author information

Correspondence to Norimichi Kan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kan, N., Ohgaki, K., Inamoto, T. et al. Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract. Cancer Immunol Immunother 18, 215–222 (1984). https://doi.org/10.1007/BF00205514

Download citation

Keywords

  • Spleen Cell
  • Plasmacytoma
  • Adoptive Immunotherapy
  • 104E Cell
  • Neutralization Assay